HomeAI · summaries
Storia in 4 fonti
Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices
Dr Reddys shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher solvent and freight costs due to the Middle East conflict further squeezed EBITDA margins.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Q1 FY27 preview: Dr Reddy’s likely to face pressure on earnings
Dr Reddy's FY27 Q1 preview indicates potential earnings pressure, with analysts predicting significant declines in profit and EBITDA.
- ·
Dr Reddy's Q1 profit falls 69% to ₹434 crore as lenalidomide transition weighs
Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.
